Year All 2026 2025 November 12, 2026 Windward Bio Announces Pricing of Initial Public Offering Read More September 8, 2026 Windward Bio announces positive Phase 2 results of WIN378 in asthma demonstrating significant improvements in lung function and airway inflammation with twice-yearly dosing, and initiates Phase 3 Read More June 9, 2026 Windward Bio Doses First Patients in Phase 2 SIRIUS COPD Study of Ultra Long-Acting Anti-TSLP Antibody WIN378 Read More May 4, 2026 Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential Read More
September 8, 2026 Windward Bio announces positive Phase 2 results of WIN378 in asthma demonstrating significant improvements in lung function and airway inflammation with twice-yearly dosing, and initiates Phase 3 Read More
June 9, 2026 Windward Bio Doses First Patients in Phase 2 SIRIUS COPD Study of Ultra Long-Acting Anti-TSLP Antibody WIN378 Read More
May 4, 2026 Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential Read More
